1. Malaysia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Duopharma Biotech Bhd.

Duopharma Biotech Bhd.

MMYX:DPHARMA
1.10
MYR
0.00
(0.00%)
11.20P/E
Nov 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.28
0.3
0.43
0.36
0.54
0.57
0.65
0.61
0.69
0.73
0.74
0.85
0.97
0.97
Basic EPS, GAAP
0.06
0.06
0.06
0.03
0.05
0.05
0.06
0.06
0.07
0.07
0.05
0.07
0.09
0.11
Free Cash Flow per Basic Share
0.05
0.04
-0.15
- -
-0.02
-0.02
0.01
0.01
-0.08
- -
0.01
0.05
0.08
0.06
Dividend per Share
0.03
0.04
0.05
0.03
0.02
0.02
0.01
0.01
0.05
0.01
0.01
0.03
0.04
0.05
Book Value per Share
0.31
0.33
0.52
0.52
0.55
0.55
0.58
0.68
0.66
0.69
0.71
0.74
0.79
0.82
Tangible Book Value per Share
0.31
0.33
0.51
0.51
0.53
0.52
0.55
0.65
0.62
0.64
0.67
0.69
0.75
0.78
Basic Weighted Avg Shares
583
583
627
868
868
875
894
928
928
948
959
962
962
962
Sales/Revenue/Turnover
162
177
270
313
468
499
576
570
639
697
705
814
932
929
Operating Margin (%)
24.74
26.43
18.6
10.22
11.5
13.53
13.47
14.22
13.9
13.27
11.75
12.37
14.36
16.35
Depreciation Expense
8
8
22
23
24
25
27
29
32
36
43
45
46
45
Net Income, GAAP
32
35
36
27
42
48
55
59
66
70
53
63
87
102
Effective Tax Rate (%)
19.66
24.14
23.91
14.78
17.98
20.15
21.94
23.04
20.85
17.37
16.79
21.72
23.88
23.9
Profit Margin (%)
19.87
19.93
13.49
8.57
9.07
9.55
9.59
10.28
10.28
10.06
7.47
7.7
9.39
11
Working Capital
76
84
280
263
235
145
178
309
264
277
510
548
505
543
LT Debt
- -
- -
104
92
91
122
141
254
300
297
482
467
345
337
Total Equity
183
194
450
455
480
481
530
644
624
655
687
709
758
786
Return on Invested Capital (%)
17.96
18.7
9.95
4.78
7.51
8.08
7.97
7.15
7.1
7.2
5.93
6.4
8.21
9.26
Return on Capital (%)
18.16
18.75
10.22
5.5
7.92
8.06
8.09
7.3
7.17
7.34
5.8
6.78
8.59
9.67
Return on Common Equity (%)
18.28
18.75
11.31
5.93
9.09
9.92
10.94
9.99
10.36
10.96
7.84
8.97
11.93
13.43

Capital Structure

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
147
141
135
LT Borrowings
345
341
337
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
962
962
962
Market Capitalization
1,202
1,222
1,145

Working Capital

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
819
825
844
Cash, Cash Equivalents & STI
291
271
256
Accounts Receivable, Net
224
253
277
Inventories
293
297
305
Total Current Liabilities
314
315
301
Payables & Accruals
- -
- -
- -
ST Debt
147
141
135
Deferred Revenue
- -
- -
- -

Growth Rates

MYR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.54%
3.37%
6.84%
Free Cash Flow
-132.79%
-458.01%
49.33%
Net Income, GAAP
11.88%
10.5%
39.62%
Sales/Revenue/Turnover
13.88%
10.45%
14.5%
Total Cash Common Dividend
56.75%
135.44%
25%

Quarterly Revenue

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
193
218
209
194
814
2025
263
222
222
225
932
2026
248
234
- -
- -
- -

Quarterly Earnings Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.02
0.07
2025
0.03
0.02
0.02
0.02
0.09
2026
0.03
0.03
- -
- -
- -

Quarterly Dividends Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
0.01
- -
0.03
2025
0.02
- -
0.02
- -
0.04
2026
0.03
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wan Amir Jeffery bin Wan Abdul Majid
Full Time Employees
2,001
Sector
Health technology
Industry
Pharmaceuticals: major
Address
CIMB HUB Klang SE Malaysia 50250
IPO Date
Jun 18, 2002
Website
duopharmabiotech.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Duopharma Biotech Berhad, an investment holding company listed on Bursa Malaysia (7148.KL), researches, develops, manufactures, distributes and imports pharmaceutical products and medicines primarily in Malaysia and select export markets. The company offers a broad portfolio of generic and halal-certified pharmaceuticals in forms including tablets, capsules, syrups, oral antibiotics, creams, hemodialysis solutions, sterile irrigation solutions, sterile powders, small volume injectables, dental cartridges and eye drops; over-the-counter consumer healthcare products under brands such as Champs, Flavettes, Proviton, Naturalle, Uphamol, Eye Glo, Donna and Alucid encompassing analgesics, antihistamines and related categories; prescription products under the Omesec brand; and specialty offerings including biopharmaceuticals, biosimilars and insulin products developed in partnership with entities like Biocon. Founded in 1979 with roots tracing to 1978 and headquartered in Klang, Selangor, Malaysia, Duopharma Biotech operates manufacturing facilities in Klang, Bangi and Glenmarie, with subsidiaries in the Philippines and Singapore, a representative office in Indonesia and exports to Vietnam, Ethiopia, Sudan, Southeast Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, Yemen, Singapore and Hong Kong; it functions as a subsidiary of Permodalan Nasional Berhad following a name change from CCM Duopharma Biotech Berhad in February 2019. Recent developments include securing MYR578 million supply contracts in April 2024 under the government's approved products purchase list, including insulin supplies via Pharmaniaga; clinching additional supply deals from Pharmaniaga; achieving first-in-Malaysia halal certification for a biosimilar product under MS2424:2019; shifting production to the new K3 facility for optimization while planning expansions at K2 and K5 for biologicals capability; and opening an office in Indonesia to enhance ASEAN presence, alongside expected earnings growth from a stronger ringgit, lower API costs and full-year contributions from 2024 contracts.